These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14639946)

  • 1. [Treatment outcome of myelodysplastic syndrome patients younger than 60 years old].
    Matsushima T; Handa H; Yokohama A; Sakura T; Okamoto K; Kawamura T; Tsumita Y; Murayama K; Isoda A; Jinbo T; Hirabyashi H; Sawamura M; Karasawa M; Shimano S; Tsukamoto N; Miyawaki S; Nojima Y; Murakami H
    Rinsho Ketsueki; 2003 Oct; 44(10):1004-9. PubMed ID: 14639946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
    Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemopoietic cell transplantation for the myelodysplastic syndromes.
    Scott BL; Deeg HJ
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
    Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T
    Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.
    Lee JH; Lee JH; Lim SN; Kim DY; Kim SH; Lee YS; Kang YA; Kang SI; Jeon MJ; Seol M; Seo EJ; Chi HS; Park CJ; Jang S; Yun SC; Lee KH
    Bone Marrow Transplant; 2010 Mar; 45(3):450-7. PubMed ID: 19668236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Outcome of allogeneic stem cell transplantation for hematological disorders in patients older than 50].
    Fujimaki K; Takasaki H; Takabayashi M; Yamaji S; Koharazawa H; Kanamori H; Ishigatsubo Y
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):47-51. PubMed ID: 15675581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
    Chan GW; Foss FM; Klein AK; Sprague K; Miller KB
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):753-9. PubMed ID: 14677114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
    Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
    Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
    Fujimaki K; Taguchi J; Fujita H; Hattori M; Yamazaki E; Takahashi N; Fujisawa S; Kanamori H; Maruta A; Ishigatsubo Y
    Bone Marrow Transplant; 2004 Apr; 33(8):789-92. PubMed ID: 15064685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
    Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.